Abstract Number: 802 • 2012 ACR/ARHP Annual Meeting
Milnacipran Reduces Brain Activity During Pain in Fibromyalgia
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition characterized by widespread musculoskeletal pain and a number of concomitant symptoms such as fatigue, sleep disturbance, cognitive…Abstract Number: 803 • 2012 ACR/ARHP Annual Meeting
Frontal Brain Connectivity to the Default Mode Network Is Associated with Subjective Fatigue Irrespective of Pain and Depression
Background/Purpose: Chronic pain patients report increased levels of fatigue; however, very little is known about the underlying mechanisms of this symptom. Previous work by our…Abstract Number: 804 • 2012 ACR/ARHP Annual Meeting
A Comparison of the Nociceptive Flexion Reflex, Pressure Algometry and Summated Widespread Pain in the Diagnosis of Fibromyalgia
Background/Purpose: To reevaluate the usefulness of the nociceptive flexion reflex (NFR) in distinguishing between FM patients and healthy controls, compared to computerized algometry and a…Abstract Number: 805 • 2012 ACR/ARHP Annual Meeting
Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia
Background/Purpose: Fibromyalgia (FM) is a chronic widespread pain disorder characterized by muscle tenderness, fatigue, poor sleep, and mood disturbance. Milnacipran is a dual serotonin-norepinephrine reuptake…Abstract Number: 806 • 2012 ACR/ARHP Annual Meeting
Posterior Insula Combined Glutamate and Glutamine Is Associated with Pain in Fibromyalgia: A Replication Study
Background/Purpose: Central pain augmentation resulting from enhanced excitatory and/or decreased inhibitory neurotransmission is a proposed mechanism underlying the pathophysiology of functional pain syndromes such as…Abstract Number: 807 • 2012 ACR/ARHP Annual Meeting
Predictors of Rheumatoid Arthritis: Quantitative and Semiquantitative Sonographic Measurements of Peripheral Joints
Background/Purpose: Sonographic quantitative and semiquantitative measurements in peripheral joints of normal subjects are yet to be defined, as are sonographic predictors of rheumatoid arthritis (RA).…Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…Abstract Number: 809 • 2012 ACR/ARHP Annual Meeting
Ultrasonography Predicts Achievement of Deeper Remission After DAS28-Based Clinical Remission of Rheumatoid Arthritis
Background/Purpose: Although clinical remission is an agreeable goal of treatment in rheumatoid arthritis (RA), the definition is still controversial. Indeed, progressive structural damage is often…Abstract Number: 810 • 2012 ACR/ARHP Annual Meeting
Assessment of Omeract Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate
Background/Purpose: The first international trial using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) synovitis scoring system1 showed early and significant signs of improvement in…Abstract Number: 811 • 2012 ACR/ARHP Annual Meeting
The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept-Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate
Background/Purpose: An exploratory study using the standardized global OMERACT Power Doppler Ultrasonography (PDUS) scoring system1 in patients (pts) with established RA and inadequate response to…Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…